Davis Aaron I.'s Form 4 filing
Rain Oncology Inc. · filed May 24, 2023
- Accession no.
- 0000895345-23-000356
- Filed
- May 24, 2023, 8:05 PM ET
- Trade date
- May 22, 2023
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 1 non-derivative transaction. Open-market sales total $1.24M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Davis Aaron I.CIK 0001465914 | Director |
| Lewis JosephCIK 0001015747 | Other: See remarks. |
| Boxer Asset Management Inc.CIK 0001465836 | Other: See remarks |
| Boxer Capital, LLCCIK 0001465837 | Other: See remarks. |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 22, 2023 | Common Stock | SSaleDisposed | −995,000 | $1.25F1 | −$1,243,750 | 1,152,212 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.18 to $1.30, inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.
Remarks
Aaron Davis, the CEO of Boxer Capital, LLC, is a director of Rain Oncology Inc.